Xencor Appoints Bart Cornelissen as Chief Financial Officer
April 09 2024 - 8:01AM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies for the treatment of
cancer and other serious diseases, today announced the appointment
of Bart Cornelissen to senior vice president and chief financial
officer. Mr. Cornelissen has more than 20 years of experience in
corporate financial planning, analysis and transaction support.
Before joining Xencor, he was most recently vice president,
corporate finance at Seagen Inc., where he was instrumental in the
company’s transformation into a global, multi-product organization
that generated over $2 billion in annual revenue.
“Bart’s exceptional track record in financial planning and
analysis, business development and organizational excellence will
be of great value to Xencor as we advance our maturing
clinical-stage pipeline of drug candidates and continue to explore
our XmAb® platforms against novel biology,” said Bassil Dahiyat,
Ph.D., president and chief executive officer at Xencor. “Throughout
his career, Bart has demonstrated collaborative leadership during
periods of organizational growth, including in the run up to
commercialization, as well as a dedication to improving health
across the globe, and we are delighted that he has joined our
team.”
As vice president, corporate finance at Seagen, Mr. Cornelissen
built and scaled the corporate finance organization to support
tremendous revenue growth and dealmaking activity, including
multiple licensing transactions and the company’s $43 billion
acquisition by Pfizer in 2023. Before Seagen, while at the Bill
& Melinda Gates Foundation, he served as vice president,
finance for the END Fund, through which he enhanced the fund’s
financial analysis and strategic decision-making capabilities. He
had also been the Gates Foundation’s finance lead for malaria and
neglected tropical disease initiatives, where he guided new
investments for major drug and vaccine development partnerships.
Earlier in his career, Mr. Cornelissen provided leadership to
multiple finance teams in Austria, Germany and Switzerland, at DSM
Nutritional Products, a former division of Roche. He began his
career within the life sciences and global health sectors at
Novartis, in roles of increasing responsibility within global
financial planning and analysis. Mr. Cornelissen received his M.Sc.
in Business Administration from the Rotterdam School of Management
at Erasmus University.
“Xencor has earned a longstanding reputation as a leader in
protein engineering, with its XmAb technologies behind multiple
products marketed by partners and collaborations that have
continued to enable reinvestment in novel drug candidates for
development,” said Mr. Cornelissen. “I am pleased to join Xencor to
support planning and capitalization for the company’s growth, as
its internal pipeline, focused on XmAb bispecific T cell engagers
in oncology, advances through clinical development.”
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies for the treatment of patients with cancer and
other serious diseases. More than 20 candidates engineered with
Xencor's XmAb® technology are in clinical development, and three
XmAb medicines are marketed by partners. Xencor's XmAb engineering
technology enables small changes to a protein's structure that
result in new mechanisms of therapeutic action. For more
information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to the quotations from Xencor's president and chief
executive officer, quotations from Xencor’s senior vice president
and chief financial officer, and other statements that are not
purely statements of historical fact. Such statements are made on
the basis of the current beliefs, expectations, and assumptions of
the management of Xencor and are subject to significant known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements and the timing of
events to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. Such risks include,
without limitation, the risks associated with the process of
discovering, developing, manufacturing and commercializing drugs
that are safe and effective for use as human therapeutics and other
risks, including the ability of publicly disclosed preliminary
clinical trial data to support continued clinical development and
regulatory approval for specific treatments, in each case as
described in Xencor's public securities filings. For a discussion
of these and other factors, please refer to Xencor's annual report
on Form 10-K for the year ended December 31, 2023 as well as
Xencor's subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended to
date. All forward-looking statements are qualified in their
entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409569704/en/
Charles Liles cliles@xencor.com 626-737-8118
For Media: Cassidy McClain Inizio Evoke
cassidy.mcclain@inizioevoke.com 619-694-6291
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Aug 2023 to Aug 2024